TriangleHEALTH PROFESSIONAL · SOURCE READING
Second Relapse After Initial Treatment With Autologous HSCT
Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 16, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of Primary Refractory or Recurrent Hodgkin Lymphoma in Children and Adolescents
In a phase II study, patients (median age, 26.5 years) who had relapsed or refractory disease after autologous HSCT received brentuximab vedotin, with an objective response rate of 73% and a complete remission rate of 34%. Patients who achieved a complete remission (n = 34) had a 3-year PFS rate of 58% and a 3-year OS rate of 73%. Only 6 of 34 patients proceeded to allogeneic HSCT while in remission.[23][Level of evidence B4]
Source links and citations
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice